Trial Profile
Rituximab in the Treatment of Chronic Lymphocytic Leukemia, "CLL NIS"
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Oct 2018
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors Roche
- 09 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 31 Jul 2015 Planned End Date changed from 1 Jun 2015 to 1 Aug 2015 as reported by ClinicalTrials.gov.
- 31 Jul 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Aug 2015 as reported by ClinicalTrials.gov record.